SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO, Director | 2026-09-08 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-09-08 | Open-market sell 10b5-1 | 4991 | $1.1M |
| FARRELL PETER C | Director | 2026-09-02 | Open-market sell 10b5-1 | 970 | $228K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-08-07 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-08-07 | Open-market sell 10b5-1 | 4991 | $1.0M |
| FARRELL PETER C | Director | 2026-08-05 | Open-market sell 10b5-1 | 8000 | $1.8M |
| Farrell Michael J. | Chairman and CEO, Director | 2026-07-07 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-07-07 | Open-market sell 10b5-1 | 4991 | $1.1M |
| Farrell Michael J. | Chairman and CEO, Director | 2026-06-08 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-06-08 | Open-market sell 10b5-1 | 4991 | $968K |
| Rider Michael J | Global General Counsel | 2026-06-01 | Tax withholding | 269 | $51K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-05-07 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-05-07 | Open-market sell 10b5-1 | 4991 | $1.0M |
| Farrell Michael J. | Chairman and CEO, Director | 2026-04-07 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-04-07 | Open-market sell 10b5-1 | 4991 | $1.1M |
| FARRELL PETER C | Director | 2026-04-01 | Open-market sell 10b5-1 | 2000 | $450K |
| Sandercock Brett | Chief Financial Officer | 2026-04-01 | Open-market sell 10b5-1 | 1000 | $224K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-03-09 | Option exercise 10b5-1 | 4991 | $730K |
| Farrell Michael J. | Chairman and CEO, Director | 2026-03-09 | Open-market sell 10b5-1 | 4991 | $1.3M |
| FARRELL PETER C | Director | 2026-03-04 | Open-market sell 10b5-1 | 2000 | $520K |
Fiscal period ending 2026-06-30 versus 2025-06-30 — view filing on EDGAR →
ResMed's risk profile has deteriorated materially and broadly, driven by a wave of acquisition-related exposures (VirtuOx, Noctrix, MatrixCare separation) layered onto pervasive regulatory escalation across FDA, CMS, Stark Law, Pillar Two tax, and Trump Administration healthcare policy uncertainty. The worsening spans at least six distinct themes — regulatory compliance, litigation, M&A execution, cybersecurity/AI, market competition, and asset impairment risk — meeting the bar for major intensity. Two nominal easings (removal of AI-specific regulatory language and goodwill impairment disclosure) appear to reflect disclosure reorganization rather than resolved risk, and do not offset the breadth of new exposures.
12 company-specific · 1 eased/removed · 5 common-mode
New material liability exposure from VirtuOx acquisition. Professional malpractice claims in diagnostic services could exceed insurance coverage, creating uninsured liability risk.
We are subject to potential professional services liability claims due to our recent acquisition of VirtuOx, which may exceed the scope and amount of our insurance coverage, which would expose us to…
New direct federal healthcare oversight from acquisitions of IDTF and DME/device businesses subject to Medicare enrollment and FDA regulation. Material regulatory exposure.
We are subject to new areas of direct healthcare oversight by federal government agencies due to our acquisitions of VirtuOx and Noctrix. In 2025, we acquired VirtuOx, a software-enabled independent…
New disclosure of material M&A and divestiture risks, including MatrixCare separation, goodwill impairment exposure, and integration execution challenges affecting earnings and cash flows.
Failure to identify, execute, and integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures. As part of our…
New disclosure of heightened policy uncertainty under Trump Administration regarding healthcare reform, Medicaid, ACA, and reimbursement—core revenue drivers for ResMed. Explicitly warns of material adverse impact risk.
RESMED INC. AND SUBSIDIARIES federal spending on Medicaid and Marketplace coverage by approximately $1.1 trillion over the 2025-2034 period, increase the federal deficit by approximately $3.4…
New disclosure of material reimbursement risks: CMS competitive bidding program changes, Noctrix coverage uncertainty, and AHRQ CPAP efficacy study questioning long-term outcomes. Directly threatens revenue and profitability.
RESMED INC. AND SUBSIDIARIES who provide services must compete to offer products in designated competitive bidding areas, or CBAs. The DMEPOS Competitive Bidding Program (CBP) remains in a temporary…
New risk factor added: professional services liability from VirtuOx acquisition. Also expanded healthcare oversight risk to include Noctrix acquisition, signaling increased M&A activity and integration complexity.
ITEM 1A RISK FACTORS Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described below in addition to the other cautionary statements and risks…
Acquisition of Noctrix (DME supplier) adds new regulatory risks: Stark Law exposure, corporate practice of medicine liability, heightened governmental scrutiny of DME/IDTF industries, increased audit and investigation risk.
RESMED INC. AND SUBSIDIARIES Medicare-enrolled DME supplier, Noctrix, are each subject to laws, regulations and policies pertaining to their Medicare enrollment, state Medicaid participation, and…
Addition of Stark Law compliance obligations and Noctrix acquisition creates new direct regulatory exposure and strict liability risk for physician referral violations.
RESMED INC. AND SUBSIDIARIES participation in Federal healthcare programs. Violations of the Federal Anti-Kickback Statute can also result in significant criminal penalties and imprisonment; • the…
New disclosure of material regulatory risk: FDA shutdown delays could impair product approvals and market access for medical device company dependent on timely regulatory review.
RESMED INC. AND SUBSIDIARIES be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 43 days…
New disclosure of expanded marketing activities and digital health dependency. Adds risk that marketing efforts may fail and patient adoption of digital platforms may not materialize, affecting demand.
Our business depends on our ability to effectively educate and engage dealers of home healthcare products, sleep clinics and physicians, health care providers, and patients regarding the benefits of…
New disclosure of third-party technology interoperability risks and dependency on strategic partnerships for digital ecosystem competitiveness. Escalates technology risk beyond internal defects.
RESMED INC. AND SUBSIDIARIES which may cause disruptions in availability or other performance problems. We have from time to time found defects in our products and may discover additional defects in…
QMSR now effective February 2026 with expanded FDA oversight of audits, suppliers, and management review. Requires ongoing process updates and compliance maintenance.
We are subject to substantial regulation related to quality standards applicable to our manufacturing and quality processes. Our failure to comply with these standards could have an adverse effect on…
Removal of goodwill impairment risk disclosure suggests resolved or reduced acquisition-related asset risk. Material if impairments were previously likely or pending.
RESMED INC. AND SUBSIDIARIES resources. There can be no assurance that any of the acquisitions we make will be successful or will be, or will remain, profitable. Moreover, we have recorded intangible…
Pillar Two minimum tax shifted from anticipated future impact to confirmed material impact on FY2026 income tax expense and cash flows.
RESMED INC. AND SUBSIDIARIES payments. As additional guidance is made available, we will continue evaluating the future impact of the Bill to our consolidated financial statements. Additionally…
New material risk: AI integration in products creates operational, regulatory, and reputational exposure. Evolving AI regulations may delay products and increase compliance costs.
RESMED INC. AND SUBSIDIARIES Our use of artificial intelligence in certain products, software solutions and business operations may expose us to operational, regulatory and reputational risks that…
Substantially expanded disclosure of AI-enabled cyberattack risks, remote work vulnerabilities, and third-party breach exposure. Escalates threat sophistication and operational disruption risk.
Actual or attempted breaches of security, unauthorized disclosure of information, attacks which reduce availability of systems such as denial of service, or the perception that personal and/or other…
Removal of AI-specific regulatory risks, including EU AI regulations, FTC bias concerns, and competitive/legal liability from AI deployment.
Our business activities are subject to extensive regulation, and any failure to comply could have a material adverse effect on our business, financial condition, or results of operations . We are…
Expanded disclosure of FDA regulatory tightening: new 510(k) requirements, potential product sunsets, clinical trial mandates, and modernization proposals. Materially increases regulatory risk and compliance costs.
Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline. Unless a…
Fiscal period ending 2025-06-30 versus 2024-06-30 — view filing on EDGAR →
ResMed's risk profile has deteriorated sharply and broadly, driven by a wave of new regulatory exposures from the VirtuOx acquisition (HIPAA covered-entity status, Civil Monetary Penalties, Anti-Kickback, False Claims Act), a $3.2M OIG settlement with a five-year CIA, and sweeping new reimbursement threats from CMS payment cuts, Medicaid rollbacks, and ACA reform uncertainty. Macro risks have simultaneously escalated via specific U.S. tariff exposure, China rare-earth export controls, and new geopolitical flashpoints, while competitive pressure intensified with GLP-1 drugs now described as capable of eliminating OSA entirely. The single deletion of prior geopolitical specifics (UFLPA, Russia-Ukraine) is insufficient to offset pervasive worsening across at least six distinct themes.
14 company-specific · 1 eased/removed · 7 common-mode
VirtuOx acquisition materially expands regulatory exposure: new IDTF Medicare/Medicaid obligations, Anti-Kickback Statute, False Claims Acts, HIPAA covered entity status, fraud/abuse risks, and compliance resource requirements.
We are subject to new areas of direct healthcare oversight by federal government agencies due to our acquisition of VirtuOx. In May 2025, we acquired VirtuOx, a software-enabled IDTF and provider of…
New disclosure of $3.2M settlement and five-year CIA with OIG for False Claims Act violations. Ongoing compliance costs and exclusion risk from federal healthcare programs materially impact operations and liquidity.
RESMED INC. AND SUBSIDIARIES On May 11, 2022, VirtuOx entered into a civil settlement of $3.2M and agreed to a five-year CIA with the OIG which resolved allegations that, from January 2016 to…
New disclosure of material policy uncertainty under Trump Administration. ResMed faces direct reimbursement risk from ACA changes, Medicare cuts, and healthcare reform. Substantive new risk to revenue and operations.
RESMED INC. AND SUBSIDIARIES Despite the ACA going into effect over a decade ago, there have been numerous legal and Congressional challenges to the law’s provisions and the effects of certain…
Prior year text was incomplete/truncated. This year adds substantial detail on business continuity impacts, insurance limitations, third-party manufacturer reliance, and regulatory compliance costs—material operational and financial risks.
Climate change and natural disasters, or other events beyond our control, could negatively impact our business operations and financial condition. Natural disasters and other business disruptions…
New material regulatory risks added: CMS 2.93% PFS payment cut for 2025, VA disability rating reductions for sleep apnea, and Medicaid spending cuts of ~$1 trillion reducing coverage eligibility.
RESMED INC. AND SUBSIDIARIES Other federal legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 required, among other things, mandatory…
New disclosure of reimbursement risk tied to third-party studies. Material for healthcare company dependent on payor coverage for revenue.
RESMED INC. AND SUBSIDIARIES reimbursement. Decreases in third-party reimbursement for our products or a decision by a third-party payor to not cover our products as a result of a third-party study…
New disclosure of direct Civil Monetary Penalties Law exposure following VirtuOx acquisition, creating beneficiary inducement prohibition liability previously inapplicable to device manufacturer.
We are subject to various risks relating to our compliance with fraud and abuse laws and transparency laws relating to our interactions with our customers, healthcare providers, and patients, which…
Company newly disclosed it is a HIPAA covered entity (VirtuOx), not just a business associate. This materially expands regulatory obligations, direct liability, and breach notification requirements.
Our use and disclosure of personal information, including health information, is subject to federal, state and foreign privacy, artificial intelligence, data, biometrics and security regulations, and…
New disclosure of active tax audits (ATO 2018, multiple open years 2018–2024) with explicit risk of material adjustments, penalties, and interest. Specific transfer pricing challenges disclosed.
We are subject to ongoing tax audits by various local tax authorities, some of which are aggressively pursuing taxes on discontinued local operations. Our income tax returns are based on calculations…
Tax risk escalated: added "aggressively pursued" language and disclosed ongoing audits on discontinued operations, signaling heightened tax exposure.
RESMED INC. AND SUBSIDIARIES • The success of our software offerings depends substantially on customers entering, renewing, upgrading and expanding their agreements for cloud services, term…
Escalated competitive threat: GLP-1s now described as "approved" for diabetes/weight loss with potential to "reduce severity or existence of OSA"; Philips ban now explicitly creates opportunity for smaller competitors; AI competition added to software segment.
RESMED INC. AND SUBSIDIARIES Risk Factors Risks Related to Our Business and Industry Our inability to compete with new and existing technology to treat OSA successfully may harm our business. The…
Added substantive new risks: clinical trials are "very expensive," "difficult to design," subject to "rigorous regulatory requirements," "time consuming," and failure can occur at any stage, requiring abandonment or repetition.
Our products are the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, and could have a…
New explicit risk: failed or delayed IT infrastructure improvements causing business disruption or materially increased costs. Adds "obsolescence" and "migration/updates" as vulnerabilities. Escalates implementation risk.
We are increasingly dependent on information technology systems and infrastructure. Failed, substandard or delayed efforts to improve our IT System infrastructure may result in disruption to our…
New disclosure of VirtuOx acquisition with "additional risk areas" and resource investment, escalating acquisition integration risk beyond prior generic language.
We may not be able to realize the anticipated benefits from acquisitions, which could adversely affect our operating results. Part of our growth strategy includes acquiring businesses consistent with…
Substantial deletion of specific geopolitical and trade risks (UFLPA, Russia-Ukraine conflict, supply chain disruption warnings) reduces disclosed risk exposure materially.
We are subject to various risks relating to international activities that could affect our overall profitability. We manufacture substantially all of our products outside the U.S. and sell a…
Substantial new disclosure of U.S. tariffs and retaliatory trade measures as material risks to operations, costs, demand, and financial results. Escalates from generic supply chain discussion to specific tariff exposure.
RESMED INC. AND SUBSIDIARIES revenue, lower prices for our products, or reduced reimbursement rates by third-party payors, while increasing the cost of operating our business. Macroeconomic…
New disclosure of China export controls on rare earth materials and magnets, with specific geopolitical risks, tariffs, and potential supply disruptions requiring costly mitigation.
RESMED INC. AND SUBSIDIARIES Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth Disruptions in the supply of components from our suppliers could result in a…
New disclosure of AI-enabled cyberattacks (generative-AI phishing, deepfakes, automated vulnerability discovery, adaptive malware) and explicit statement that material cyberattack could cause material business disruption.
RESMED INC. AND SUBSIDIARIES malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and…
Significant expansion of regulatory risk disclosure. Added detailed GDPR obligations, UK GDPR, state omnibus privacy laws, and data transfer complexity—material new compliance burdens and operational constraints.
RESMED INC. AND SUBSIDIARIES business associate agreements often have shorter notification timeframes which we are required to abide by contractually. We could also face contractual liability if we…
New disclosure of Pillar Two global minimum tax expected to impact effective tax rate in fiscal 2026, plus One Big Beautiful Bill R&D deduction changes. Material tax law developments with quantifiable forward impact.
RESMED INC. AND SUBSIDIARIES Tax laws, regulations, and enforcement practices are evolving, are aggressively pursued in some jurisdictions, and may cause expense as well as management distraction…
Added explicit tariff and trade war risks as direct threats to suppliers and operations, escalating macroeconomic risk disclosure.
Global macroeconomic conditions, including the direct and indirect effects of inflation, supply chain disruptions, reciprocal tariffs, and fluctuations in foreign currency exchange rates, could…
Added Israel-Iran conflict risk, expanded geopolitical scenario analysis, and broader supply chain/market impact warnings. Escalates disclosed geopolitical exposure.
RESMED INC. AND SUBSIDIARIES years ended June 30, 2025 and June 30, 2024, respectively. Our sales and operations outside of the U.S. are subject to several difficulties and risks that are separate…
ResMed entered into a $450 million accelerated share repurchase (ASR) agreement with Citibank on August 31, 2026. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs" alongside dividends and distributions. The materiality is clear given the substantial $450 million size and the company's explicit mention of this transaction in its FY2027 guidance during the Q4 FY26 earnings call.
View raw filing on EDGAR →KPMG LLP was dismissed as the Company's principal accountant effective August 13, 2026, and PricewaterhouseCoopers LLP was appointed as the new independent registered public accounting firm for the fiscal year ending June 30, 2027. No disagreements or reportable events with KPMG were disclosed.
View raw filing on EDGAR →Ronald Taylor, a director and Lead Director of Resmed for over 21 years, announced his retirement from the Board effective at the November 2026 Annual Meeting, and Carol Burt was appointed as his successor in the Lead Director role effective November 15, 2026. This represents a board-level governance transition in the Lead Director position.
View raw filing on EDGAR →Resmed disclosed quarterly and fiscal year 2026 financial results for the period ended June 30, 2026, reporting revenue growth of 9% to $1.5 billion in Q4 and 10% to $5.7 billion for FY2026, with detailed financial statements and EPS metrics included in the earnings announcement.
View raw filing on EDGAR →Resmed announced a quarterly cash dividend of $0.66 per share, representing a 10% increase from the previous dividend, with a record date of August 20, 2026 and payment date of September 24, 2026.
View raw filing on EDGAR →ResMed entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction expected to close in Q1 fiscal 2027. The disposition represents approximately $220 million in annual revenue and $55 million in non-GAAP operating profit, reflecting a strategic portfolio shift toward high-growth sleep and connected care markets. The company plans to return net proceeds to shareholders via an accelerated share repurchase program.
View raw filing on EDGAR →